Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA. Longer term follow-up data will be presented from the pivotal CARTITUDE-1 study in patients with relapsed or refractory multiple myeloma.
🌍 Legend Biotech (LEGN) - Form 6-K Filing
Filing Date: 2022-05-18
Accepted: 2022-05-18 08:30:28
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
📞 Contact Information: